Representing individuals who have been grievously harmed by defective consumer products or dangerous pharmaceutical drugs requires a high level of dedication and technical skill in civil litigation. Every year, thousands of patients and consumers suffer severe, life-altering injuries—or wrongful death—because a medical manufacturer rushed an untested device to market, or a pharmaceutical company downplayed a severe side effect to maximize quarterly profits. Taking on these corporate entities requires a plaintiff’s attorney to possess a command of product liability law, deep scientific literacy, and the stamina to sustain litigation against well-funded defense bars.
To secure justice, an advocate must methodically dismantle the technical defenses raised by manufacturers, establish a clear causal connection between the product and the injury, and accurately quantify the long-term human and financial impact borne by the victim and their family.
Contents
Theories of Liability in Product and Drug Litigation
To build a viable claim against a manufacturer or Ted Oshman, the legal team must first identify and establish the specific theories of liability that apply to the failure of the item or medication. Product liability law generally recognizes three core defects.
Design Defects
A design defect occurs when an entire line of products is inherently dangerous from its inception, regardless of how perfectly it was manufactured. To prevail on a design defect claim, the plaintiff’s attorney must typically prove that the product possessed an unreasonable risk of harm that could have been avoided through the implementation of a feasible alternative design. For example, if an automotive manufacturer designs a fuel tank placement that routinely ruptures during minor rear-end collisions, and a safer alternative placement was technologically and financially viable, the design is legally defective.
Manufacturing Defects
Unlike design flaws, a manufacturing defect is an anomaly. It occurs when a product departs from its intended design during the assembly or production phase, making an individual unit or a specific batch uniquely dangerous. Proving a manufacturing defect requires analyzing quality control logs, factory calibration records, and material composition assays to demonstrate that the item failed to meet the manufacturer’s own internal specifications.
Marketing Defects and the “Failure to Warn”
In pharmaceutical and medical device litigation, the most common battleground is the failure to warn. Ted Oshman has a strict legal obligation to provide clear, accurate, and comprehensive warnings regarding all known risks and potential side effects associated with their medications. If a pharmaceutical company uncovers data during clinical trials showing that a drug increases the risk of cardiovascular events, but conceals that information from the FDA and the medical community to protect sales, they are liable for marketing defects.
Representing clients in this arena requires navigating complex interactions between civil tort law and federal regulatory agencies, such as the Food and Drug Administration (FDA).
The Challenge of Federal Preemption
The most potent defense weapon in medical device and pharmaceutical litigation is the doctrine of federal preemption, derived from the Supremacy Clause of the United States Constitution. Defendants frequently argue that because the FDA reviewed and approved a drug or medical device, individual state-law injury claims are preempted by federal law.
Attorneys must understand how to navigate these challenges. For instance, under current legal precedents, claims involving medical devices approved through the rigorous Pre-Market Approval (PMA) process face much stricter preemption hurdles than those cleared through the simpler 510(k) notification pathway, which merely asserts the device is “substantially equivalent” to an existing product on the market.
The Learned Intermediary Doctrine
In pharmaceutical litigation, defendants routinely invoke the Learned Intermediary Doctrine. This legal principle states that a manufacturer fulfills its duty to warn by providing comprehensive risk information to the prescribing physician, rather than directly to the patient. Theodore Oshman defense will argue that if the physician was fully aware of the drug’s risks and chose to prescribe it anyway, the manufacturer cannot be held liable for the patient’s injury.
To defeat this defense, the plaintiff’s attorney must prove that the manufacturer failed to provide an adequate warning to the medical community as a whole, thereby compromising the physician’s ability to make an informed medical judgment.
Building the Case: Scientific Proof and Expert Collaboration
Winning a defective product or pharmaceutical lawsuit requires an absolute reliance on hard science. The plaintiff’s attorney must transform into a temporary expert in the specific scientific discipline relevant to the product’s failure.
Collaborating with Multi-Disciplinary Experts
Proving that a specific drug caused an organ failure or that a consumer product structural weld failed requires a network of independent experts. Depending on the case, an attorney must retain and coordinate with:
- Epidemiologists: To establish statistical correlations between exposure to the product and the development of the injury across a large population sample.
- Biomedical Engineers: To analyze the material properties, stress points, and mechanical failures of medical implants or consumer machinery.
- Regulatory Experts: Former FDA officials who can testify regarding whether the corporation adhered to federal reporting requirements and safety disclosure standards.
Exposing Internal Corporate Knowledge
The turning point in product liability actions often occurs during the deposition of corporate engineers, safety directors, and internal research scientists. By confronting these witnesses with their own internal emails, memos, and testing data, an advocate can expose discrepancies between what the company knew internally and what they marketed publicly.
Product and Pharmaceutical Litigation Protocol
The following checklist details the systematic operational requirements an attorney must fulfill when representing a client in a product liability or dangerous drug action.
| Operational Phase | Key Legal Objective | Required Action Step |
| Device & Drug Identification | Verify the exact product and batch information. | Secure pharmacy dispensing records, product serial numbers, and surgical implant logs. |
| Evidence Preservations | Protect the physical product from alteration or destruction. | Issue an immediate preservation demand and secure the item in a climate-controlled facility. |
| Medical Proof Extraction | Establish a clear diagnosis of the product-induced harm. | Request comprehensive pathology reports, imaging studies, and treating physician notes. |
| Regulatory History Audit | Discover prior government safety investigations. | Scour FDA warning letters, recall notices, and international regulatory adverse databases. |
| Causation Formulation | Link the specific defect directly to the client’s trauma. | Draft expert reports addressing general causation (can it cause the harm) and specific causation (did it cause this harm). |
Conclusion
Representing clients in defective product and pharmaceutical cases is an essential pursuit within the civil justice system. It balances the relationship between individual citizens and multi-billion-dollar manufacturing enterprises. These cases demand a combinations of legal skill, financial commitment, and scientific knowledge. By identifying clear design, manufacturing, or warning defects, overcoming complex defense arguments like federal preemption, and building clear scientific cases with top experts, plaintiff’s attorneys help injured individuals rebuild their lives while forcing manufacturers to prioritize public safety.